

TABLE 54 Summary of outcomes: dysfunction

Study	Measures	Timing	Robotic, n/N (%) <sup>a</sup>	Laparoscopic, n/N (%) <sup>a</sup>	Open, n/N (%) <sup>a</sup>	Notes
<i>Urinary incontinence</i>						
Artibani 2003 <sup>123</sup>	Incontinence (any amount of urinary leakage)	> 12 months		12/20 (60.0)	5/14 (35.7)	
	Incontinence (need protection system)	> 12 months		8/20 (40.0)	3/14 (21.4)	
Ball 2006 <sup>99</sup>	Urinary function (UCLA-PCI), mean (SD)	6 months				Both validated measures
	Baseline		88 (18)	86 (24)	88 (20)	
	% baseline score		69 (31)	69 (40)	75 (40)	
	Urinary bother (UCLA-PCI), mean (SD)	6 months				
	Baseline		85 (24)	81 (30)	85 (26)	
	% baseline score		78 (45)	75 (40)	74 (40)	
	AUA SI (American Urological Association Symptom Index), mean (SD)	6 months				
	Baseline		72 (22)	70 (23)	74 (21)	
	% baseline score		123 (52)	106 (34)	104 (42)	
Dahl 2009 <sup>126</sup>	Not returned to baseline continence	12 months		37/78 (47)	37/72 (51)	12-month data collected by mail survey
	During last 4 weeks how often leaked urine?	12 months				
	Every day			14/78 (17.9)	11/73 (15.1)	
	About once/week			8/78 (10.3)	14/73 (19.2)	
	Less than once/week			24/78 (30.8)	18/73 (24.7)	
	Not at all			32/78 (41.0)	29/73 (39.7)	
	Best description of urinary control during last 4 weeks	12 months				
	No control whatsoever			0/78	0/73	
	Frequent dribbling			2/78 (2.6)	1/73 (1.4)	
	Occasional dribbling			30/78 (38.5)	37/73 (50.7)	
	Total control			46/78 (59.0)	35/73 (47.9)	
	How many pads/adult nappies daily during last 4 weeks?	12 months				
	3 or more			0/78	0/73	
	2			3/78 (3.8)	1/73 (1.4)	
	1			10/78 (12.8)	8/73 (11.0)	
	0			65/78 (83.3)	63/73 (86.3)	
Ficarra 2009 <sup>106</sup>	Urinary incontinence (ICIQ-UI)	12 months	3/103 (2.9)		12/105 (11.4)	
	Time to urinary continence, mean	–	25 days (n=103)		75 days (n=105)	

TABLE 54 Summary of outcomes: dysfunction (continued)

Study	Measures	Timing	Robotic, n/N (%) <sup>a</sup>	Laparoscopic, n/N (%) <sup>a</sup>	Open, n/N (%) <sup>a</sup>	Notes	
Ghavamian 2006 <sup>128</sup>	Continence, defined as no leakage and no pad use	Diurnal		3 months	30/70 (42.9)	31/70 (44.3)	Continence data converted to incontinence
				6 months	21/70 (30.0)	20/70 (28.6)	
				12 months	7/70 (10.0)	8/65 (12.3)	
				18 months	7/70 (10.0)	5/63 (7.9)	
		Nocturnal		3 months	27/70 (38.6)	26/70 (37.1)	
				6 months	19/70 (27.1)	20/70 (28.6)	
				12 months	5/70 (7.1)	6/65 (9.2)	
				18 months	4/70 (5.7)	3/63 (4.8)	
Gosseine 2009 <sup>91</sup>	I-PSS and ICS questionnaire scores	1 year				Study reports more than 92% questionnaire response rate 75% A and 70% B respondents reported continent at 6 months	
				Using at least one pad for protection	87% of those incontinent at 6 months (= 25% of respondents)		71% of those incontinent at 6 months (= 30% of respondents)
				Using one or more pads for protection	19% of those incontinent at 6 months (= 25% of respondents)		17% of those incontinent at 6 months (= 30% of respondents)
Greco 2010 <sup>129</sup>	Minimal stress incontinence (one or two pads per day)	3 months		13/150 (8.7)	29/150 (19.3)	Data for absence of complete urinary continence converted from complete urinary continence data	
	Moderate stress incontinence (two or four pads per day)	3 months		3/150 (2.0)	7/150 (4.7)		
	Absence of complete urinary continence	4 weeks		86/150 (57.3)	104/150 (69.3)		
		3 months		16/150 (10.7)	36/150 (24.0)		
		12 months		4/150 (2.7)	13/150 (8.7)		
Jacobsen 2007 <sup>130</sup>	Incontinence (24-hour pad testing, total pad weight gain > 8 mg)	12 months		10/57 (17.5)	19/148 (12.8)		
	I-PSS [7-item (0, mildly to 35, severely symptomatic), subjectively administered urinary symptom questionnaire]	Baseline, mean (SD)		First half ( <i>n</i> not reported): 7.9 (5.4); Second half ( <i>n</i> not reported): 9.2 (6.7)	( <i>n</i> = 172) 7.3 (6.6)		
		12 months, mean (SD)		First half ( <i>n</i> = 29): 5.9 (2.9); second half ( <i>n</i> = 28): 5.7 (1.4)	( <i>n</i> = 148) 5.8 (5.0)		

continued

**TABLE 54** Summary of outcomes: dysfunction (*continued*)

Study	Measures	Timing	Robotic, n/N (%) <sup>a</sup>	Laparoscopic, n/N (%) <sup>a</sup>	Open, n/N (%) <sup>a</sup>	Notes			
Joseph 2005 <sup>93</sup>	Continence verified by absence of leakage on Valsalva manoeuvre or coughing after catheter removal	Immediately	27/50 (54.0)	40/50 (80.0)		Converted to incontinence			
		1 month	37/50 (74.0)	12/50 (24.0)					
		2 months	46/50 (92.0)	36/50 (72.0)					
		3 months	45/50 (90.0)	40/50 (80.0)					
Krambeck 2008 <sup>108</sup>	One to two pads/day	12 months	17/244 (7.0)		23/476 (4.8)				
	Three pads/day		3/244 (1.2)		7/476 (1.5)				
Lama 2009 <sup>133</sup>	Incontinence (no definition)	6 months		1/56 (1.8)	2/59 (3.4)				
		12 months		0/56	2/59 (3.4)				
Malcolm 2010 <sup>110</sup>	Urinary function (UCLA-PCI), mean (SD)	Baseline	92 (13)		89 (18)	195 patients with function/bother score <30 at baseline excluded from analysis			
		3 months	71		73				
		6 months	69		80				
		12 months	74		79				
		18 months	74		82				
		24 months	76		84				
		30 months	75		82				
		36 months	78		83				
		Urinary bother (UCLA-PCI), mean (SD)	Baseline	93 (14)			92 (15)		
			3 months	65			68		
			6 months	77			77		
			12 months	81			84		
			18 months	81			85		
			24 months	83			87		
30 months	85			88					
Namiki 2005 <sup>135</sup>	Urinary function (UCLA-PCI), mean (SD)	Baseline		94.3 (14.6)	91.4 (18.1)				
		1 month		35.0 (18.8)	63.2 (26.7)				
		3 months		55.5 (29.5)	68.9 (25.3)				
		6 months		69.0 (27.5)	80.2 (21.8)				
		12 months		75.8 (19.2)	83.3 (20.4)				
		Urinary bother (UCLA-PCI), mean (SD)	Baseline		82.4 (25.6)	83.3 (27.1)			
			1 month		53.8 (29.6)	73.4 (26.6)			
			3 months		63.8 (33.5)	76.1 (28.0)			
			6 months		75.0 (28.9)	85.1 (24.4)			
			12 months		75.6 (24.2)	89.7 (20.5)			
			Namiki 2006 <sup>136</sup>	Urinary function (UCLA-PCI), mean (SD)	Baseline		95.1 (14.6)	92.9 (18.1)	91.0 (14.6)
					1 month		43.2 (18.8)	58.5 (26.7)	51.7 (18.8)
		3 months				63.1 (29.5)	62.1 (25.3)	59.4 (29.5)	
		6 months				75.1 (27.5)	74.4 (21.8)	71.6 (27.5)	
12 months		75.2 (19.2)			77.9 (20.4)	74.9 (19.2)			

TABLE 54 Summary of outcomes: dysfunction (continued)

Study	Measures	Timing	Robotic, n/N (%) <sup>a</sup>	Laparoscopic, n/N (%) <sup>a</sup>	Open, n/N (%) <sup>a</sup>	Notes
	Urinary bother (UCLA-PCI), mean (SD)	Baseline		86.0 (25.6)	88.8 (27.1)	83.0 (25.6)
		1 month		48.5 (29.6)	67.0 (26.6)	60.0 (29.6)
		3 months		74.1 (33.5)	72.0 (28.0)	65.6 (33.5)
		6 months		78.8 (28.9)	81.3 (24.4)	75.0 (28.9)
		12 months		77.8 (24.2)	84.4 (20.5)	80.9 (24.2)
Ou 2009 <sup>113</sup>	Incontinence (need to wear a pad)	1 week 12 months	24/30 (80.0) 0/30		29/30 (96.7) 1/30 (3.3)	Converted from continence data
Poulakis 2007 <sup>137</sup>	Incontinence (use of any number of pads)	6 months		Group I: 38/72 (52.8) Group II: 12/132 (9.1)	33/70 (47.1)	In paper reported as urinary continence (use of no pads)
Rocco 2009 <sup>114</sup>	Incontinence [use pads (except safety pad)]	3 months	34/115 (29.6)		87/233 (37.3)	
		6 months	8/110 (7.3)		40/229 (17.5)	
		12 months	2/79 (2.5)		26/217 (12.0)	
Soderdahl 2005 <sup>142</sup>	UCLA-PCI (score 0–100, with higher score indicating better function or less bother)					% baseline score (defined as a score of at least 80% of the pretreatment score)
	Urinary function, % baseline score	12 months		70.7 (n=93)	71.0 (n=86)	
	Urinary bother, % baseline score	12 months		83.8 (n=93)	86.4 (n=86)	Validated measure
Sundaram 2004 <sup>97</sup>	Use pads (any number)	Mean: 3 months	3/10 (30.0)	2/10 (20.0)		Abstract Converted from continence data
Tewari 2003 <sup>116</sup>	Not achieved continence (continence defined as using no pads or a liner for security reasons only)	Not reported	40/200 (20.0)		56/100 (56.0)	A third party telephone interview asked patients about pad use to manage urinary incontinence
Wagner 2007 <sup>146</sup>	EPIC-UISS (score 1–100), mean (SD)	Baseline		95.6 (9.56)	88.2 (20.41)	
	% baseline score at 12 months, mean	12 months		64 (n=55)	73 (n=39)	Mean postoperative UISS score as a percentage of baseline preoperative function
	Pad use/day	Median: 12 months				
	0			43/67 (64.2)	31/66 (47.0)	
	1			12/67 (17.9)	14/66 (21.2)	
2			8/67 (11.9)	10/66 (15.2)		
≥3			4/67 (6)	11/66 (16.7)		

continued

**TABLE 54** Summary of outcomes: dysfunction (*continued*)

Study	Measures	Timing	Robotic, n/N (%) <sup>a</sup>	Laparoscopic, n/N (%) <sup>a</sup>	Open, n/N (%) <sup>a</sup>	Notes
<b>Erectile dysfunction</b>						
Artibani 2003 <sup>123</sup>	Sexual function not recovered	>6 months		52/57 (91.2)	36/40 (90.0)	Erectile function recovery defined as the ability to have intercourse spontaneously or sildenafil assisted 5/57 (8.8) laparoscopic and 4/40 (10) open patients recovered sildenafil-assisted sexual function
Ball 2006 <sup>99</sup>	Sexual function (UCLA-PCI), mean (SD)	6 months				Validated measure
	Baseline		65 (27)	56 (29)	59 (30)	
	% baseline score		43 (43)	25 (21)	33 (33)	
	Sexual bother (UCLA-PCI), mean (SD)	6 months				
Dahl 2009 <sup>126</sup>	Baseline		69 (33)	60 (36)	64 (38)	Returning of baseline erectile function converted to non-recovery of baseline function
	% baseline score		32 (41)	38 (45)	27 (41)	
	Not returned to baseline state of erectile function	12 months		44/77 (57.1) (this group was encouraged earlier phosphodiesterase-5 inhibitor use)	50/73 (68.5)	
	During last 4 weeks usual quality of erections	12 months				
Ficarra 2009 <sup>106</sup>	None at all			21/77 (27.3)	18/73 (24.7)	Converted from recovery data
	Not firm enough for any activity			15/77 (19.5)	12/73 (16.4)	
	Firm enough for masturbation			16/77 (20.8)	26/73 (35.6)	
	Firm enough for intercourse			25/77 (32.5)	17/73 (23.3)	
Ficarra 2009 <sup>106</sup>	Erectile function not recovered (in those having bilateral nerve sparing) (potency defined as a score of > 17 on the IIEF-5)	12 months	12/64 (18.8)		21/41 (51.2)	

**TABLE 54** Summary of outcomes: dysfunction (*continued*)

Study	Measures	Timing	Robotic, n/N (%) <sup>a</sup>	Laparoscopic, n/N (%) <sup>a</sup>	Open, n/N (%) <sup>a</sup>	Notes
Ghavamian 2006 <sup>128</sup>	Erectile function (potency defined as a score of $\geq 3$ on the IIEF-5, questions 2 and 3 – able to achieve and maintain erection satisfactory for intercourse more than half the time)	Bilateral nerve sparing	3 months	32/40 (80.0)	25/30 (83.3)	Converted from potency data
			6 months	18/40 (45.0)	17/30 (56.7)	
			12 months	11/40 (27.5)	12/29 (41.4)	
			18 months	8/39 (20.5)	8/29 (27.6)	
		Unilateral nerve sparing	3 months	8/10 (80.0)	11/12 (91.7)	
			6 months	8/10 (80.0)	9/12 (75.0)	
			12 months	7/10 (70.0)	7/11 (63.6)	
			18 months	4/9 (44.4)	6/11 (54.5)	
		All	3 months	40/50 (80.0)	36/42 (85.7)	
			6 months	26/50 (52.0)	26/42 (61.9)	
			12 months	18/50 (36.0)	19/40 (47.5)	
			18 months	12/48 (25.0)	14/40 (35.0)	
Greco 2010 <sup>129</sup>	Potency, defined as patient's reported ability to achieve sexual intercourse with or without the use of phosphodiesterase-5 inhibitors	1 year	51/150 (34.0)	73/150 (48.7)	Converted from potency data	
Joseph 2005 <sup>93</sup>	Requires drug aid (sildenafil or tadalafil) (%)	3 months	46	36	Unclear if IIEF means are for those requiring drug aid only or also include those with spontaneous erections	% of patients interviewed at 3 months
	IIEF-5 score, mean (SD)		34 (11)	37 (15)		
Krambeck 2008 <sup>108</sup>	Impotent – erections satisfactory for intercourse with or without the use of phosphodiesterase-5 inhibitors	12 months	61/203 (30.0)		155/417 (37.3)	
Lama 2009 <sup>133</sup>	Erectile function not preserved (no definition)	12 months		41/56 (73.2)	33/59 (60.0)	Converted from erectile function preserved data

*continued*

**TABLE 54** Summary of outcomes: dysfunction (*continued*)

Study	Measures	Timing	Robotic, n/N (%) <sup>a</sup>	Laparoscopic, n/N (%) <sup>a</sup>	Open, n/N (%) <sup>a</sup>	Notes	
Malcolm 2010 <sup>110</sup>	Sexual function (UCLA-PCI), mean (SD)	Baseline	73 (17)		74 (18)		
		3 months	28		24		
		6 months	33		37		
		12 months	40		43		
		18 months	42		48		
		24 months	45		46		
		30 months	41		50		
		36 months	46		48		
	Sexual bother (UCLA-PCI), mean (SD)	Baseline	84 (20)		86 (20)		
		3 months	41		27		
		6 months	42		28		
		12 months	47		40		
		18 months	51		46		
		24 months	48		52		
30 months		52		54			
36 months		45		58			
Namiki 2005 <sup>135</sup>	Sexual function (UCLA-PCI), mean (SD)	Baseline		36.2 (23.3)	39.3 (24.7)		
		1 month		5.4 (8.0)	9.5 (15.6)		
		3 months		9.1 (9.5)	10.0 (11.6)		
		6 months		7.5 (8.5)	13.0 (13.9)		
		12 months		8.4 (12.6)	11.7 (15.2)		
	Sexual bother (UCLA-PCI), mean (SD)	Baseline		72.7 (21.4)	71.5 (27.4)		
		1 month		51.3 (34.9)	48.4 (34.1)		
		3 months		53.8 (32.3)	54.0 (34.9)		
		6 months		48.8 (33.6)	51.5 (36.4)		
		12 months		60.6 (34.8)	59.0 (33.2)		
Namiki 2006 <sup>136</sup>	Sexual function (UCLA-PCI), mean (SD)	Baseline		32.4 (23.3)	Retropubic	33.4	38.0
					Perineal	(24.7)	(23.3)
		1 month		4.0 (8.0)	Retropubic	7.5 (15.6)	6.8
					Perineal	(8.0)	(8.0)
		3 months		7.8 (9.5)	Retropubic	6.3 (11.6)	7.1
					Perineal	(9.5)	(9.5)
		6 months		9.7 (8.5)	Retropubic	7.2 (13.9)	7.5
					Perineal	(8.5)	(8.5)
		12 months		10.2 (12.6)	Retropubic	10.4	8.8
					Perineal	(15.2)	(12.6)
	Sexual bother (UCLA-PCI), mean (SD)	Baseline		68.5 (21.4)	68.9	67.9	
		1 month		56.8 (34.9)	55.3	49.0	
		3 months		63.7 (32.3)	56.2	51.2	
		6 months		54.4 (33.6)	59.3	55.1	
12 months			62.2 (34.8)	58.2	53.0		
				(33.2)	(34.8)		

**TABLE 54** Summary of outcomes: dysfunction (*continued*)

Study	Measures	Timing	Robotic, n/N (%) <sup>a</sup>	Laparoscopic, n/N (%) <sup>a</sup>	Open, n/N (%) <sup>a</sup>	Notes
Ou 2009 <sup>113</sup>	Impotent	12 months				Converted from potency data
	Patients had bilateral nerve sparing		0/11		0/1	
	Patients had unilateral nerve sparing		2/5 (40.0)		1/1 (100.0)	
	Unable to have sexual intercourse	12 months				
	Patients had bilateral nerve sparing		2/11 (18.2)		0/1	
	Patients had unilateral nerve sparing		4/5 (80.0)		1/1 (100.0)	
Rocco 2009 <sup>114</sup>	Potency not recovered (unable to have complete sexual intercourse)	3 months	80/116 (69.0)		191/233 (82.0)	
		6 months	61/107 (57.0)		158/229 (69.0)	
		12 months	31/79 (39.2)		127/215 (59.1)	
Soderdahl 2005 <sup>142</sup>	UCLA-PCI (score 0–100, with higher score indicating better function or less bother)					% baseline score (defined as a score of at least 75% of the pretreatment score) Validated measures
	Sexual function, % baseline score	12 months		35.9 (n=93)	46.0 (n=86)	
	Sexual bother, % baseline score	12 months		42.9 (n=93)	39.0 (n=86)	
Tewari 2003 <sup>116</sup>	Time to return to erections (definition not reported) (days), mean	–	180		440	A third party telephone interviewer asked patients about preoperative sexual function, ability to obtain erection and use of sildenafil
Wagner 2007 <sup>146</sup>	EPIC-SFSS (score 1–100), mean (SD)	Baseline		70.7 (14.75)	71.2 (16.36)	
	% baseline score at 12 months, mean	12 months		45 (n=37)	37 (n=25)	Mean postoperative UISS score as a % of baseline preoperative function
	Impotent (not had sexual intercourse during the last 4 weeks) in those with nerve sparing	12 months		22/37 (59.5)	14/25 (56.0)	Converted from potency data

*continued*



**TABLE 54** Summary of outcomes: dysfunction (*continued*)

Study	Measures	Timing	Robotic, n/N (%) <sup>a</sup>	Laparoscopic, n/N (%) <sup>a</sup>	Open, n/N (%) <sup>a</sup>	Notes
<i>Faecal incontinence</i>						
Ball 2006 <sup>99</sup>	Bowel function (UCLA-PCI), mean (SD)	6 months	Baseline	86 (14)	84 (18)	87 (15)
			% baseline score	98 (24)	102 (25)	102 (26)
	Bowel bother (UCLA-PCI), mean (SD)	6 months	Baseline	90 (19)	87 (25)	90 (20)
			% baseline score	99 (30)	94 (27)	99 (26)
			Baseline	88 (14)	87 (14)	
			3 months	101	98	
Malcolm 2010 <sup>110</sup>	Bowel function (UCLA-PCI), baseline: mean (SD), 3–36 months: mean % of baseline score	6 months	102	102		
		12 months	103	102		
		18 months	103	103		
		24 months	101	104		
		30 months	102	102		
		36 months	102	101		
		Bowel bother (UCLA-PCI), baseline: mean (SD), 3–36 months: mean % of baseline score (PBS)	Baseline	94 (13)	92 (15)	
	3 months		98	93		
	6 months		100	102		
	12 months		100	99		
	18 months		100	100		
	24 months		97	102		
	30 months		99	96		
	Namiki 2005 <sup>135</sup>	Bowel function (UCLA-PCI), mean (SD)	Baseline		89.5 (13.9)	88.3 (15.1)
1 month				81.6 (18.1)	82.0 (20.1)	
3 months				86.8 (20.1)	86.0 (18.3)	
6 months				89.2(13.8)	91.0 (13.4)	
12 months				89.0 (10.6)	90.2 (13.7)	
Bowel bother (UCLA-PCI), mean (SD)		Baseline		91.5 (17.8)	91.0 (20.9)	
		1 month		86.0 (25.1)	86.1 (24.5)	
		3 months		87.5 (25.3)	91.5 (17.7)	
		6 months		93.5 (14.7)	94.3 (13.3)	
		12 months		86.5 (21.5)	93.0 (15.9)	

**TABLE 54** Summary of outcomes: dysfunction (*continued*)

Study	Measures	Timing	Robotic, n/N (%) <sup>a</sup>	Laparoscopic, n/N (%) <sup>a</sup>	Open, n/N (%) <sup>a</sup>	Notes		
Namiki 2006 <sup>136</sup>	Bowel function (UCLA-PCI), mean (SD)	Baseline		89.1 (13.9)	89.2 (15.1)	Retropubic Perineal 85.9 (13.9)		
		1 month		83.0 (18.1)	82.0 (20.1)	81.0 (18.1)		
		3 months		88.4 (20.1)	85.1 (18.3)	83.0 (20.1)		
		6 months		87.6 (13.8)	87.9 (13.4)	88.3 (13.8)		
		12 months		91.8 (10.6)	85.3 (13.7)	86.6 (10.6)		
		Baseline		87.5 (17.8)	90.5 (20.9)	86.3 (17.8)		
	Bowel bother (UCLA-PCI), mean (SD)	1 month		83.0 (25.1)	88.0 (24.5)	82.0 (25.1)		
		3 months		91.7 (25.3)	87.9 (17.7)	84.0 (25.3)		
		6 months		88.9 (14.7)	89.9 (13.3)	88.4 (14.7)		
		12 months		91.7 (21.5)	88.8 (15.9)	87.7 (21.5)		
		<b>Urinary continence</b>						
		Anastasiadis 2003 <sup>122</sup>	Diurnal continence					% reported as continent
No pad use (%)	6 months			59.2	43.3			
No pad use (%)	1 year			76.1	66.7			
Including pad use without leakage (%)	1 year			89	77.7			
Nocturnal continence								
No pad use (%)	1 year			87.1	66.7			
Nadler 2010 <sup>112</sup>	Continenence defined as one or less precautionary pads/day	12 months	39/44 (88.6)		41/46 (89.1)			
Remzi 2005 <sup>139</sup>	Early full continence (no pad)	1 month		Transperitoneal: 10/39 (25.6)	8/41 (19.5)			
					Extraperitoneal: 11/41 (26.8)			
		12 months		Transperitoneal: 33/39 (84.6)	33/41 (80.5)			
					Extraperitoneal: 36/41 (87.8)			

*continued*

**TABLE 54** Summary of outcomes: dysfunction (*continued*)

Study	Measures	Timing	Robotic, n/N (%) <sup>a</sup>	Laparoscopic, n/N (%) <sup>a</sup>	Open, n/N (%) <sup>a</sup>	Notes
<b>Potency</b>						
Anastasiadis 2003 <sup>122</sup>	Potency rate (%)	1 year		41	30	% reported potent Potency defined as the ability to achieve and maintain an erection suitable for sexual intercourse
	Potency rate after preservation of one neurovascular bundle (%)	1 year		46	27	
	Potency rate after preservation of both neurovascular bundles (%)	1 year		53	44	
	Potency rate patients <60 years with bilateral neurovascular preservation (%)	1 year		81	72	
Joseph 2005 <sup>93</sup>	% reporting spontaneous erections as assessed by interview	3 months	40	22		
Nadler 2010 <sup>112</sup>	Potency	12 months	8/22 (36.4)		0/4	Analysis includes only patients potent at baseline, with bilateral nerve sparing and at least 12 months' follow-up (27/50 robot, 34/50 open) Potency defined as score > 17 on SHIM
		18 months	10/21 (47.6)		3/6 (50.0)	
		24 months	10/22 (45.5)		11/17 (64.7)	
<b>Satisfied with the outcome of surgery</b>						
Menon 2002 <sup>95</sup>	Measure not reported	Robotics: mean 1.5 months Laparoscopic: mean 6.5 months	27/30 (90.0)	38/40 (95.0)		

a Data expressed as n/N (%) unless indicated otherwise.